FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

2.

Recent research suggests that vitamin supplements may increase the risk of developing cancer.

3.

The way that miR-377 inhibits cells that cause prostate cancer.

4.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says

5.

Durvalumab Wins FDA Approval in Limited-Stage SCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot